### Fold reduced neutralizing susceptibility (compared to Omicron/BA.2) to monoclonal antibodies under Emergency Use Authorization (EUA)

[table noHeaderOverlapping]
table_mab_ba2
[/table]

### Fold reduced neutralizing susceptibility (compared to Omicron/BA.2) to monoclonal antibodies in other clinical trials

[table noHeaderOverlapping]
table_mab_ba2_non_eua
[/table]

- The fold reduction in susceptibility is the median value of results, the
  subscript is the number of samples. “-” indicates absence of susceptibility
  data.
- Spike mutations:
  - **Omicron/BA.2**: T19I, L24S, PPA25-27∆, G142D, V213G, G339D, S371F, S373P,
    S375F, T376A, D405N, R408S, K417N, N440K, S477N, T478K, E484A, Q493R, Q498R,
    N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K
  - **Omicron/BA.2.12.1**: T19I, L24S, PPA25-27∆, G142D, V213G, G339D, S371F,
    S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K, E484A,
    Q493R, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H,
    N969K
  - **Omicron/BA.2.75**: T19I, L24S, PPA25-27∆, G142D, K147E, W152R, F157L,
    I210V, V213G, G257S, G339H, S371F, S373P, S375F, T376A, D405N, R408S,
    K417N, N440K, G446S, N460K, S477N, T478K, E484A, Q498R, N501Y, Y505H,
    D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K
  - **Omicron/BA.2.75.2**: T19I, L24S, PPA25-27∆, G142D, K147E, W152R, F157L,
    I210V, V213G, G257S, G339H, R346T, S371F, S373P, S375F, T376A, D405N, R408S,
    K417N, N440K, G446S, N460K, S477N, T478K, E484A, F486S, Q498R, N501Y, Y505H,
    D614G, H655Y, N679K, P681H, N764K, D796Y, Q954H, N969K, D1199N
  - **Omicron/BA.4**: T19I, L24S, PPA25-27∆, HV69-70∆, G142D, V213G, G339D,
    S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K,
    E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y,
    Q954H, N969K
  - **Omicron/BA.5**: T19I, L24S, PPA25-27∆, HV69-70∆, G142D, V213G, G339D,
    S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K,
    E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N679K, P681H, N764K, D796Y,
    Q954H, N969K
  - **Omicron/BA.4.6**: T19I, L24S, PPA25-27∆, HV69-70∆, G142D, V213G, G339D, R346T,
    S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, L452R, S477N, T478K,
    E484A, F486V, Q498R, N501Y, Y505H, D614G, H655Y, N658S, N679K, P681H, N764K, D796Y,
    Q954H, N969K
  - **Omicron/XBB**: T19I, L24S, PPA25-27∆, V83A, G142D, Y144∆, H146Q, Q183E, V213E,
    G339H, R346T, L368I, S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, V445P,
    G446S, N460K, S477N, T478K, E484A, F486S, F490S, Q498R, N501Y, Y505H, H655Y, N679K,
    P681H, N764K, D796Y, Q954H, N969K
  - **Omicron/BQ.1**: T19I, L24S, PPA25-27∆, HV69-70∆, G142D, V213G, G339D, S371F,
    S373P, S375F, T376A, D405N, R408S, K417N, N440K, K444T, L452R, N460K, S477N,
    T478K, E484A, F486V, Q498R, N501Y, Y505H, H655Y, N679K, P681H, N764K, D796Y,
    Q954H, N969K
  - **Omicron/BQ.1.1**: T19I, L24S, PPA25-27∆, HV69-70∆, G142D, V213G, G339D, R346T,
    S371F, S373P, S375F, T376A, D405N, R408S, K417N, N440K, K444T, L452R, N460K, S477N,
    T478K, E484A, F486V, Q498R, N501Y, Y505H, H655Y, N679K, P681H, N764K, D796Y,
    Q954H, N969K
- Monoclonal antibody(mAb) abbreviations: **BAM**:
  Bamlanivimab/LY-CoV555/LY3819253, **ETE**: Etesevimab/LY-CoV016/JS016/CB6,
  **CAS**: Casirivimab/REGN10933, **IMD**: Imdevimab/REGN10987, **CIL**:
  Cilgavimab/COV2-2130/AZD1061, **TIX**: Tixagevimab/COV2-2196/AZD8895, **SOT**:
  Sotrovimab/Vir-7831/S309, **BEB**: Bebtelovimab/LY-CoV1404/LY3853113, **REG**:
  Regdanvimab/CT-P59, **AMU**: Amubarvimab/BRII-196/P2C-1f11, **ROM**:
  Romlusevimab/BRII-198/P2B-1G5, **ADI**: Adintrevimab/ADG20/ADG-2.
- The color scheme indicates the fold-reduction in neutralization:
  <span style="padding: .1rem .2rem; margin: 0 .2rem; border: 1px solid black; background-color: #ffffff; color: black;">absence of color</span>
  – &lt;5-fold reduced susceptibility;
  <span style="padding: .1rem .2rem; margin: 0 .2rem; border: 1px solid black; background-color: #7fcbee; color: black;">light blue</span>
  – 5 to 24.9-fold reduced susceptibility;
  <span style="padding: .1rem .2rem; margin: 0 .2rem; border: 1px solid black; background-color: #146aa8; color: white;">dark blue</span>
  – ≥25-fold reduced susceptibility.
